ARTICLE | Company News

Fosun gains pair of cell therapies from ReNeuron

April 9, 2019 10:53 PM UTC

ReNeuron gained 51p (30%) to 222p on Tuesday after it granted a Fosun subsidiary exclusive rights to develop and commercialize its hRPC and CTX stem cell therapies in China.

ReNeuron Group plc (LSE:RENE) will receive $7.9 million up front and is eligible for estimated milestones of $104.8 million, plus 12-14% tiered royalties...